Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 32 for:    REDUCE-IT
Previous Study | Return to List | Next Study

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01492361
Recruitment Status : Completed
First Posted : December 15, 2011
Last Update Posted : June 6, 2019
Sponsor:
Information provided by (Responsible Party):
Amarin Pharma Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 2018
Actual Study Completion Date : May 2018
Certification/Extension First Submitted : June 4, 2019
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):